98%
921
2 minutes
20
Objectives: Physician global assessments (PhyGAs) are commonly performed in randomised controlled trials (RCTs) in systemic sclerosis (SSc). However, there is no single PhyGA applied across RCTs. We performed an exploratory qualitative study to explore perceptions of the PhyGA, its role in RCTs and how physicians perform their own assessment.
Methods: Participants with expertise in the clinical assessment and research of SSc were invited to participate. Participants were asked to define disease constructs of activity, damage, severity and overall health, how they perform a PhyGA and their perception of what a PhyGA should assess. Interview transcripts were analysed using deductive and inductive thematic analysis.
Results: Eighteen rheumatologists and one patient research partner were interviewed. Four major themes were identified: i) Physician uncertainty; ii) Variation in the conduct of a PhyGA; iii) Physician efforts to improve PhyGA consistency; iv) Utility of a PhyGA. Most participants felt a PhyGA should assess changeable aspects of SSc, commonly conceived of as disease activity. There was considerable uncertainty about the optimal method to identify disease activity. Participants were uncertain about their own methods of performing a PhyGA and variability in the application of the instrument was identified. Despite these limitations, physicians generally agreed the PhyGA is useful and can assess unquantifiable aspects of SSc.
Conclusion: We identified significant heterogeneity in the approach to PhyGAs in SSc. This variation was considered a limitation of the PhyGA. Overall, a PhyGA was viewed as a useful instrument that can aid the assessment of treatment response in RCTs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keaf377 | DOI Listing |
Rheumatology (Oxford)
July 2025
Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia.
Objectives: Physician global assessments (PhyGAs) are commonly performed in randomised controlled trials (RCTs) in systemic sclerosis (SSc). However, there is no single PhyGA applied across RCTs. We performed an exploratory qualitative study to explore perceptions of the PhyGA, its role in RCTs and how physicians perform their own assessment.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
February 2025
The University of Melbourne, Melbourne, Victoria, and the University of Sydney, Sydney Musculoskeletal Health Research Flagship Centre, and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
J Allergy Clin Immunol Pract
February 2023
Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:
Rheumatol Int
November 2021
Rheumatology Clinic, Aydin State Hospital, Aydın, Turkey.
The rheumatoid arthritis impact of disease (RAID) score was developed as a patient-derived composite response index for the evaluation of the disease impact on cases with rheumatoid arthritis (RA). The aim of this study was to evaluate the psychometric properties and performance of RAID score in the real-life settings. Cases with RA from our multi-center, nationwide registry called Biologic and targeted Synthetic antirheumatic drugs Registry RA (BioStaR RA) were included in this cross-sectional observational study.
View Article and Find Full Text PDFWorld Allergy Organ J
April 2020
Novartis Pharma AG, Basel, Switzerland.
Background: Chronic urticaria (CU) is a condition characterized by recurrent itchy hives and/or angioedema for ≥6 weeks. Most of the data about CU come from western countries with very little information available about CU in Asia, Africa, and the Middle East.
Methods: AWARE-AMAC is a 24-month prospective, observational, real-world, non-interventional study in patients aged ≥18 years from Asia, the Middle East, and Africa (AMAC) with CU refractory to H1-antihistamines (H1-AH).